Therapeutic Application of Endothelial Progenitor Cells for Treatment of Cardiovascular Diseases

ISSN: 2212-3946 (Online)
ISSN: 1574-888X (Print)


Volume 9, 6 Issues, 2014


Download PDF Flyer




Current Stem Cell Research & Therapy

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 11th of 17 in Cell & Tissue Engineering
  • 98th of 185 in Cell Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Anthony Atala
Wake Forest University School of Medicine,
Medical Center Boulevard
Winston Salem, NC 27157
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.963

Therapeutic Application of Endothelial Progenitor Cells for Treatment of Cardiovascular Diseases

Author(s): Xu Jian-Yong, Lee Yee-Ki, Yu Wang and Tse Hung-Fat

Affiliation: Cardiology Division, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, P.R.China

Abstract

Cardiovascular disease is the leading cause of death worldwide. Despite significant progress in understanding of the disease mechanisms, most therapies remain at best palliative. Few therapeutic approaches offer direct tissue repair and regeneration. Cell-based therapy offers a promising approach that involves transplantation of healthy and functional cells to replenish damaged cells and repair injured tissue. Endothelial dysfunction is one of the most important mechanisms of cardiovascular disease, thus endothelial progenitor cells (EPC) and their derivatives have been investigated as a potential source for cell therapy. In pre-clinical and pilot clinical studies, treatment with EPCs or their derivatives as well as their co-transplantation with other cell types has shown some initial promising results. In this review, we will first describe the importance of endothelial cells and EPC homeostasis in the pathophysiology of cardiovascular disease. The potential sources of EPCs, including their isolation and purification, differentiation from pluripotent stem cells and adult stem cells, and trans-differentiation from somatic cells will then be summarized. Lastly, the application of target genome editing tools, such as Zinc Finger Nuclease (ZFN), Transcription Activator Like Effector Nucleases (TALEN) and RNA Guided EndoNuclease (RGEN) to modify EPCs and their derivatives will be described. These technologies promise to further improve the therapeutic potential of EPCs and their derivatives to treat cardiovascular disease


Purchase Online Rights and Permissions

Article Details

Volume: 9
First Page: 1
Last Page: 1
Page Count: 1
DOI: 10.2174/1574888X09666140619121318
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science